Ardelyx (ARDX)
(Delayed Data from NSDQ)
$6.45 USD
-0.29 (-4.30%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $6.45 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Brokerage Reports
0 items in cart
Ardelyx, Inc. [ARDX]
Reports for Purchase
Showing records 21 - 40 ( 173 total )
Company: Ardelyx, Inc.
Industry: Medical - Drugs
ScriptWatch 2023: Ibsrela, Xphozah Prescription Trends
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Ardelyx, Inc.
Industry: Medical - Drugs
XPHOZAH Shipments to U.S. Pharmacies Underway to Provide Unique Alternative to Phosphate Binders
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Ardelyx, Inc.
Industry: Medical - Drugs
The IgAN Era Continues, While Xphozah Makes A Splash Ahead Of Launch
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Ardelyx, Inc.
Industry: Medical - Drugs
Biotechnology-The Wedbush Monthly Check-Up: November 2023
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Ardelyx, Inc.
Industry: Medical - Drugs
3Q Recap; Ardelyx Firing On All Cylinders; Increasing PT to Reflect Higher Than Expected XPHOZAH Pricing; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Ardelyx, Inc.
Industry: Medical - Drugs
Get Your Commercial Engines Started -- Xphozah Prepares To Launch
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Ardelyx, Inc.
Industry: Medical - Drugs
Company: Ardelyx, Inc.
Industry: Medical - Drugs
3Q23 Commercial Preview: Some Fireworks Ahead, But Prereleases Steal Thunder
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Ardelyx, Inc.
Industry: Medical - Drugs
Company: Ardelyx, Inc.
Industry: Medical - Drugs
Xphozah Approval Call Highlights -- On To The Launch
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Ardelyx, Inc.
Industry: Medical - Drugs
Good Things Come To Those Who Wait --- Xphozah APPROVED
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Ardelyx, Inc.
Industry: Medical - Drugs
Kidney Week 2023 - Gearing Up For What''s New in Glomerular Disease
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Ardelyx, Inc.
Industry: Medical - Drugs
Company: Ardelyx, Inc.
Industry: Medical - Drugs
Company: Ardelyx, Inc.
Industry: Medical - Drugs
Tenapanor Notches A Regulatory Win Ahead Of Upcoming PDUFA
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Ardelyx, Inc.
Industry: Medical - Drugs
Tenapanor''s Approval For Hyperphosphatemia in CKD Patients With Dialysis in Japan Triggers $35M in Payments; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Ardelyx, Inc.
Industry: Medical - Drugs
Company: Ardelyx, Inc.
Industry: Medical - Drugs
It''s The Final Countdown; Check-In With Management Ahead of Tenapanor PDUFA
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Ardelyx, Inc.
Industry: Medical - Drugs
Presentations Highlight Patient Experience With IBSRELA in IBS-C
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Ardelyx, Inc.
Industry: Medical - Drugs
We initiate coverage with a Buy rating and $9.00 price target
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E